AstraZeneca puts leading COVID-19 vaccine trial on hold over safety concern
Pharmaceutical company AstraZeneca said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine because of an unexplained illness in a study participant. The vaccine, developed with the University of Oxford, has been widely seen as one of the leading global candidates against the coronavirus, and the suspension of the trial dims prospects for a potential year-end rollout its lead developer had signalled earlier.
AstraZeneca said it voluntarily paused trials to allow review of safety data by an independent committee and was working to expedite the review of the single event to minimize any potential impact on the trial timeline. “This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials,” the company said in an emailed statement. The nature of the illness and when it happened were not detailed, although the participant is expected to recover, according to Stat News, which first reported the suspension due to a “suspected serious adverse reaction”.
The suspension of the trial has impacted other AstraZeneca vaccine trials – as well as clinical trials being conducted by other vaccine makers, which are looking for signs of similar reactions, Stat said. The US National Institutes of Health, which is providing funding for AstraZeneca’s trial, declined to comment.
Trials of the vaccine, called AZD1222, are under way at different stages in Britain, the United States, Brazil, South Africa and India. Trials are also planned in Japan and Russia.